Osteonecrosis of the jaw in oncology patients treated with bisphosphonates

Prospective experience of a dental oncology referral center

Ourania Nicolatou-Galitis, Erofili Papadopoulou, Triantafyllia Sarri, Polyxeni Boziari, Aikaterini Karayianni, Marie Christine Kyrtsonis, Panagiotis Repousis, Vassilios Barbounis, Cesar Migliorati

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Objectives: The objectives of this study were to define the incidence, pain, and healing in cancer patients treated with intravenous bisphosphonates. Study design: The study included long-term follow-up of 99 bisphosphonate-using patients (group A) and conservative treatment of 67 patients with bisphosphonate-related osteonecrosis of the jaw (BRONJ, group B) using 3 antibiotic schemes and oral hygiene. Results: The frequency of zoledronic acid single-agent use was 85.9% and 69.8% in group A and B, respectively. Median follow-up was 13 months (group A) and 16 months (group B). Two patients in group A developed BRONJ (2%). Of those with BRONJ in group B who completed follow-up, healing occurred in 14.9% (7/47) and pain subsided in 80.9% (38/47). Healing was significant in patients who received pamidronate followed by zoledronic acid (P =.023) and with BRONJ stages 0 and stage I (P =.003). Conclusions: This case series suggests that oral hygiene and conservative antibiotic therapy play a role in healing and pain alleviation in BRONJ. Oral hygiene and follow-up may decrease incidence of BRONJ.

Original languageEnglish (US)
Pages (from-to)195-202
Number of pages8
JournalOral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology
Volume112
Issue number2
DOIs
StatePublished - Aug 1 2011

Fingerprint

Osteonecrosis
Diphosphonates
Jaw
zoledronic acid
Tooth
Referral and Consultation
Oral Hygiene
pamidronate
Pain
Bisphosphonate-Associated Osteonecrosis of the Jaw
Anti-Bacterial Agents
Incidence
Neoplasms

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oral Surgery
  • Otorhinolaryngology
  • Dentistry(all)

Cite this

Osteonecrosis of the jaw in oncology patients treated with bisphosphonates : Prospective experience of a dental oncology referral center. / Nicolatou-Galitis, Ourania; Papadopoulou, Erofili; Sarri, Triantafyllia; Boziari, Polyxeni; Karayianni, Aikaterini; Kyrtsonis, Marie Christine; Repousis, Panagiotis; Barbounis, Vassilios; Migliorati, Cesar.

In: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, Vol. 112, No. 2, 01.08.2011, p. 195-202.

Research output: Contribution to journalArticle

Nicolatou-Galitis, O, Papadopoulou, E, Sarri, T, Boziari, P, Karayianni, A, Kyrtsonis, MC, Repousis, P, Barbounis, V & Migliorati, C 2011, 'Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: Prospective experience of a dental oncology referral center', Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, vol. 112, no. 2, pp. 195-202. https://doi.org/10.1016/j.tripleo.2011.02.037
Nicolatou-Galitis, Ourania ; Papadopoulou, Erofili ; Sarri, Triantafyllia ; Boziari, Polyxeni ; Karayianni, Aikaterini ; Kyrtsonis, Marie Christine ; Repousis, Panagiotis ; Barbounis, Vassilios ; Migliorati, Cesar. / Osteonecrosis of the jaw in oncology patients treated with bisphosphonates : Prospective experience of a dental oncology referral center. In: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology. 2011 ; Vol. 112, No. 2. pp. 195-202.
@article{9e04275415c742d78a26008b01d8279b,
title = "Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: Prospective experience of a dental oncology referral center",
abstract = "Objectives: The objectives of this study were to define the incidence, pain, and healing in cancer patients treated with intravenous bisphosphonates. Study design: The study included long-term follow-up of 99 bisphosphonate-using patients (group A) and conservative treatment of 67 patients with bisphosphonate-related osteonecrosis of the jaw (BRONJ, group B) using 3 antibiotic schemes and oral hygiene. Results: The frequency of zoledronic acid single-agent use was 85.9{\%} and 69.8{\%} in group A and B, respectively. Median follow-up was 13 months (group A) and 16 months (group B). Two patients in group A developed BRONJ (2{\%}). Of those with BRONJ in group B who completed follow-up, healing occurred in 14.9{\%} (7/47) and pain subsided in 80.9{\%} (38/47). Healing was significant in patients who received pamidronate followed by zoledronic acid (P =.023) and with BRONJ stages 0 and stage I (P =.003). Conclusions: This case series suggests that oral hygiene and conservative antibiotic therapy play a role in healing and pain alleviation in BRONJ. Oral hygiene and follow-up may decrease incidence of BRONJ.",
author = "Ourania Nicolatou-Galitis and Erofili Papadopoulou and Triantafyllia Sarri and Polyxeni Boziari and Aikaterini Karayianni and Kyrtsonis, {Marie Christine} and Panagiotis Repousis and Vassilios Barbounis and Cesar Migliorati",
year = "2011",
month = "8",
day = "1",
doi = "10.1016/j.tripleo.2011.02.037",
language = "English (US)",
volume = "112",
pages = "195--202",
journal = "Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology",
issn = "2212-4403",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Osteonecrosis of the jaw in oncology patients treated with bisphosphonates

T2 - Prospective experience of a dental oncology referral center

AU - Nicolatou-Galitis, Ourania

AU - Papadopoulou, Erofili

AU - Sarri, Triantafyllia

AU - Boziari, Polyxeni

AU - Karayianni, Aikaterini

AU - Kyrtsonis, Marie Christine

AU - Repousis, Panagiotis

AU - Barbounis, Vassilios

AU - Migliorati, Cesar

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Objectives: The objectives of this study were to define the incidence, pain, and healing in cancer patients treated with intravenous bisphosphonates. Study design: The study included long-term follow-up of 99 bisphosphonate-using patients (group A) and conservative treatment of 67 patients with bisphosphonate-related osteonecrosis of the jaw (BRONJ, group B) using 3 antibiotic schemes and oral hygiene. Results: The frequency of zoledronic acid single-agent use was 85.9% and 69.8% in group A and B, respectively. Median follow-up was 13 months (group A) and 16 months (group B). Two patients in group A developed BRONJ (2%). Of those with BRONJ in group B who completed follow-up, healing occurred in 14.9% (7/47) and pain subsided in 80.9% (38/47). Healing was significant in patients who received pamidronate followed by zoledronic acid (P =.023) and with BRONJ stages 0 and stage I (P =.003). Conclusions: This case series suggests that oral hygiene and conservative antibiotic therapy play a role in healing and pain alleviation in BRONJ. Oral hygiene and follow-up may decrease incidence of BRONJ.

AB - Objectives: The objectives of this study were to define the incidence, pain, and healing in cancer patients treated with intravenous bisphosphonates. Study design: The study included long-term follow-up of 99 bisphosphonate-using patients (group A) and conservative treatment of 67 patients with bisphosphonate-related osteonecrosis of the jaw (BRONJ, group B) using 3 antibiotic schemes and oral hygiene. Results: The frequency of zoledronic acid single-agent use was 85.9% and 69.8% in group A and B, respectively. Median follow-up was 13 months (group A) and 16 months (group B). Two patients in group A developed BRONJ (2%). Of those with BRONJ in group B who completed follow-up, healing occurred in 14.9% (7/47) and pain subsided in 80.9% (38/47). Healing was significant in patients who received pamidronate followed by zoledronic acid (P =.023) and with BRONJ stages 0 and stage I (P =.003). Conclusions: This case series suggests that oral hygiene and conservative antibiotic therapy play a role in healing and pain alleviation in BRONJ. Oral hygiene and follow-up may decrease incidence of BRONJ.

UR - http://www.scopus.com/inward/record.url?scp=79960233317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960233317&partnerID=8YFLogxK

U2 - 10.1016/j.tripleo.2011.02.037

DO - 10.1016/j.tripleo.2011.02.037

M3 - Article

VL - 112

SP - 195

EP - 202

JO - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

JF - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

SN - 2212-4403

IS - 2

ER -